What's Happening?
Tempus AI and Pathos AI have entered into a five-year neurology data agreement potentially worth up to $55 million. This deal grants Pathos AI access to as many as 500,000 de-identified patient records for neurological conditions, including Alzheimer’s
disease. Tempus AI aims to license 100,000 records annually over five years. Pathos AI will compensate Tempus AI $100 for each delivered record, totaling up to $50 million, with an additional $5 million allocated for record updates. The agreement also involves Bristol Myers Squibb, which will gain access to Pathos AI's Foundry platform and secure three years of exclusive rights for its neuroscience development programs. Pathos AI intends to utilize this longitudinal data through its AI platform, Foundry, to test hypotheses regarding disease biology and to inform the design of clinical trials. Tempus AI's founder and CEO, Eric Lefkofsky, emphasized the necessity of extensive data and computing power to advance research into devastating diseases like Alzheimer's.
Why It's Important?
This collaboration signifies a significant advancement in the application of artificial intelligence and large-scale data in precision medicine, particularly within neurology. The access to 500,000 de-identified patient records provides a robust dataset for Pathos AI to accelerate drug discovery and development for neurological conditions. For Bristol Myers Squibb, the exclusive rights and access to the Foundry platform could streamline its neuroscience development programs, potentially leading to more effective treatments for diseases like Alzheimer's. The financial commitment of up to $55 million underscores the perceived value of real-world patient data in pharmaceutical research. This deal highlights a growing trend where technology companies specializing in AI and data analytics are becoming crucial partners for pharmaceutical giants, aiming to reduce the time and cost associated with bringing new drugs to market and personalize patient care.
What's Next?
Over the next five years, Tempus AI will work to license 100,000 de-identified neurological patient records annually to Pathos AI. Pathos AI will proceed with analyzing this longitudinal data using its Foundry AI platform to generate insights into disease biology and refine clinical trial designs. Bristol Myers Squibb will integrate its access to the Foundry platform and its exclusive rights into its ongoing neuroscience development programs. The financial terms of the agreement, including monthly invoicing for data-license fees and quarterly invoicing for update fees, will be executed as data is delivered. This neurology agreement is distinct from an existing oncology data and services agreement between Bristol Myers Squibb and Tempus AI, which has fixed payments of $137.5 million through December 31, 2031. If the neurology deal reaches its maximum value, the combined agreements would total $192.5 million in payments to Tempus AI over approximately five years.
Beyond the Headlines
This partnership exemplifies the increasing convergence of artificial intelligence, big data, and pharmaceutical research, pushing the boundaries of precision medicine. The use of de-identified patient records raises important ethical considerations regarding data privacy and security, even with anonymization efforts. The sheer volume of data involved could lead to breakthroughs in understanding complex neurological diseases, but it also necessitates robust AI models capable of accurately interpreting and deriving actionable insights from such diverse datasets. The financial structure, with payments tied to data delivery, reflects a transactional model for valuable health data, potentially setting a precedent for future collaborations. This development could also influence regulatory frameworks as the industry grapples with the implications of AI-driven drug development and the extensive use of patient data.
